All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MDS Hub spoke with Andrew Brunner, Massachusetts General Hospital, Boston, US. We asked, What treatment would you suggest for high risk MDS patients not fit for chemotherapy or hematopoietic stem cell transplantation (HSCT)?
What treatment would you suggest for high risk MDS patients not fit for chemotherapy or HSCT?
Brunner discusses the challenges associated with treatment for patients who are not fit for chemotherapy or HSCT. He goes on to discuss hypomethylating agent therapy, such as azacitidine and decitabine regimens, as well as talking about supportive care.
Outcomes of patients with CMML treated with hypomethylating agents
Hypomethylating agents (HMAs) currently remain the only approved drugs for the management of chronic myelomonocytic leukemia (CMML), with prospective, randomized controlled trials...
How have oral hypomethylating agents changed the management of MDS?
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MDS Hub spoke with Guillermo Garcia-Manero, MD Anderson Cancer Center, Houston, US. We asked, How have oral...
Subscribe to get the best content related to MDS delivered to your inbox